Pure Papillary Serous Tumors of the Endometrium

Benito, Virginia; Lubrano, Amina; Arencibia, Octavio; Álvarez, E.E.; León, Laureano; Medina, Norberto; Falcón, Juan Miguel; Falcón, Orlando

doi:10.1111/igc.0b013e3181b7a1d5

Cited by 29 publications

(14 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous reports, 3–6 USC stage II/III/IV had a higher recurrence rate in comparison to stage-matched EAC (40% Vs 22%), as well, a shorter time to relapse (5.8 months for USC vs 15.9 months for EAC). Additionally, patients with USC had worse OS of 37.2% compared to EAC 62.7%.…”

Section: Discussionsupporting

confidence: 91%

“…15 Benito et al analyzed USC tumors and found that the depth of invasion had an independent influence on OS in multivariate analysis. 6 In our series, depth of MI was the single most important factor in uterine carcinoma. MI of >50% was an independent factor in predicting DOD, OS and any poor outcome (recurrence, progression or persistence of disease) in stage II/III/IV cancer.…”

Section: Discussionmentioning

confidence: 51%

“…In most cases, by the time of USC is diagnosed, it presents as disseminated disease. 2–6 USCs are usually associated with p53 abnormalities rather than PTEN abnormalities. Because of the high risk of extra uterine spreading, women with USC ≥ stage II are usually treated with chemotherapy with or without local or regional radiation after a complete staging procedure.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium

Mhawech‐Fauceglia

Herrmann

Kesterson

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Aims To explore and to compare the outcome of patients diagnosed with stage II/III/IV and stage III/IV endometrioid adenocarcinoma (EAC) with their serous carcinoma (USC) counterparts. Materials and methods A total of 107 patients (73 EAC and 34 USC) were evaluated. For statistical analysis, the following baseline variables were considered for their prognostic value: the patient’s age at presentation, the tumor size, the depth of myometrial invasion (MI), the lympho-vascular involvement (LVI) and the USC and the EAC subtypes (considered as binary variables). Disease free survival (DFS), death of disease (DOD) and overall survival (OS) were assessed using univariate and multiple Cox proportional hazards models. Results In univariate analysis, USC tends to recur more frequently than EAC (p = 0.004), a finding that disappeared in multivariate analysis. Furthermore, tumor histology had no significance in predicting the tumor outcomes. Among all of the prognostic factors and after adjusting for the aforementioned variables, MI ≥50% was the only independent factor in predicting DOD in stages II/III/IV (p = 0.009) and in stages III/IV (p = 0.004). MI was also an independent predictive factor for OS (p = 0.02) and early recurrences in stages III/IV. LVI was the only independent factor in predicting recurrences (p = 0.004) in stages II/III/IV but not in stages III/IV. Conclusion Based on our study, tumor histology was not a significant factor in predicting disease outcome in stages II/III/IV and II/IV. Despite our limited sample size, we believe that our findings provide meaningful insights into the clinical study of endometrial cancer patients which in turn warrants further investigation.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 51%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium

Mhawech‐Fauceglia

Herrmann

Kesterson

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

show abstract

“…USC is responsible for a disproportionate number of deaths due to the fact that most of these tumors have already spread outside the uteri corpus. The 5-year survival rate for stages I–II EAC is estimated to range between 75 and 87%, and between 44 and 50% for stages I–II USC [3–4]. Numerous prognostic parameters have been implicated in endometrial carcinoma including tumor grade, tumor subtypes, tumor stage, presence of lymphovascular invasion (LVI), and depth of myometrial invasion [5,6,7].…”

Section: Introductionmentioning

confidence: 99%

Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma

Mhawech‐Fauceglia

Wang

Syriac

et al. 2012

Gynecologic Oncology

View full text Add to dashboard Cite

Objective Synuclein-γ (SNCG) is a marker for adverse and aggressive disease in breast cancer. In previous study, we found SNCG mRNA to be overexpressed in uterine serous carcinoma compared to uterine endometrioid adenocarcinoma. The aim of this study is to explore the prognostic value of SNCG in patients with endometrial cancer. Methods 279 endometrial cancer patients were retrieved from the archives. The tissue paraffin blocks were stained for SNCG antibody and its expression was correlated with clinicopathological prognostic factors. Results There was a positive association between SNCG+ immunoexpression and tumor grade, tumor stage, type II carcinomas, deep myometrial invasion and lymphovascular invasion. A correlation between SNCG+ and adverse outcomes, such as shorter overall survival (OS) and disease free survival (DFS), was also detected. Following adjuvant therapy (radiation and chemotherapy or chemotherapy alone), we observed a difference in 5 years DFS rate between SNCG+ (41.6%) and SNCG− patients (59.5%). Conclusion Overexpression of SNCG seemed to be a predictor biomarker for aggressive tumor behavior and adverse outcome in patients with endometrial cancer. Future exploration of SNCG as a potential therapeutic target for selected patients could be of interest.

show abstract

“…They are high grade tumors with deep myometrial invasion and lymphovascular involvement [5]. The 5-year survival rates are estimated to be 50% for stage II, 20% for stage III and 5–10% for stage IV disease [6].…”

Section: Introductionmentioning

confidence: 99%

Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma

et al. 2010

View full text Add to dashboard Cite

BackgroundEndometrial cancer is the most common gynecologic malignancy in developed countries and little is known about the underlying mechanism of stage and disease outcomes. The goal of this study was to identify differentially expressed genes (DEG) between late vs. early stage endometrioid adenocarcinoma (EAC) and uterine serous carcinoma (USC), as well as between disease outcomes in each of the two histological subtypes.Methodology/Principal FindingGene expression profiles of 20 cancer samples were analyzed (EAC = 10, USC = 10) using the human genome wide illumina bead microarrays. There was little overlap in the DEG sets between late vs. early stages in EAC and USC, and there was an insignificant overlap in DEG sets between good and poor prognosis in EAC and USC. Remarkably, there was no overlap between the stage-derived DEGs and the prognosis-derived DEGs for each of the two histological subtypes. Further functional annotation of differentially expressed genes showed that the composition of enriched function terms were different among different DEG sets. Gene expression differences for selected genes of various stages and outcomes were confirmed by qRT-PCR with a high validation rate.ConclusionThis data, although preliminary, suggests that there might be involvement of distinct groups of genes in tumor progression (late vs. early stage) in each of the EAC and USC. It also suggests that these genes are different from those involved in tumor outcome (good vs. poor prognosis). These involved genes, once clinically verified, may be important for predicting tumor progression and tumor outcome.

show abstract

Pure Papillary Serous Tumors of the Endometrium

Abstract: Papillary serous carcinoma of the endometrium is a very aggressive type of endometrial carcinoma that behaves more similar to ovarian carcinoma than to endometrial carcinoma. Tumor markers at diagnosis, stage, and myometrial infiltration mainly determine prognosis at our institution.

Cited by 29 publications

References 28 publications

Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium

Prognostic factors in stages II/III/IV and stages III/IV endometrioid and serous adenocarcinoma of the endometrium

Synuclein-γ (SNCG) protein expression is associated with poor outcome in endometrial adenocarcinoma

Microarray Analysis Reveals Distinct Gene Expression Profiles Among Different Tumor Histology, Stage and Disease Outcomes in Endometrial Adenocarcinoma

Contact Info

Product

Resources

About